534 related articles for article (PubMed ID: 18414108)
41. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface.
Kanamoto T; Kiuchi Y; Tanito M; Mizoue S; Naito T; Teranishi S; Hirooka K; Rimayanti U;
J Ocul Pharmacol Ther; 2015 Apr; 31(3):156-64. PubMed ID: 25710276
[TBL] [Abstract][Full Text] [Related]
43. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.
Goldberg I; Cunha-Vaz J; Jakobsen JE; Nordmann JP; Trost E; Sullivan EK;
J Glaucoma; 2001 Oct; 10(5):414-22. PubMed ID: 11711841
[TBL] [Abstract][Full Text] [Related]
44. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost.
Baudouin C; Riancho L; Warnet JM; Brignole F
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4123-8. PubMed ID: 17724196
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
[TBL] [Abstract][Full Text] [Related]
46. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.
Fellman RL; Sullivan EK; Ratliff M; Silver LH; Whitson JT; Turner FD; Weiner AL; Davis AA;
Ophthalmology; 2002 May; 109(5):998-1008. PubMed ID: 11986110
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.
Dubiner HB; Sircy MD; Landry T; Bergamini MV; Silver LH; Darell Turner F; Robertson S; Andrew RM; Weiner A; Przydryga J
Clin Ther; 2004 Jan; 26(1):84-91. PubMed ID: 14996520
[TBL] [Abstract][Full Text] [Related]
48. Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study).
Birt CM; Buys YM; Ahmed II; Trope GE;
J Glaucoma; 2010 Sep; 19(7):460-7. PubMed ID: 20051890
[TBL] [Abstract][Full Text] [Related]
49. The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension.
Arcieri ES; Pierre Filho PT; Wakamatsu TH; Costa VP
Eye (Lond); 2008 Feb; 22(2):179-83. PubMed ID: 16936646
[TBL] [Abstract][Full Text] [Related]
50. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma.
Konstas AG; Mikropoulos D; Kaltsos K; Jenkins JN; Stewart WC
Ophthalmology; 2006 Mar; 113(3):446-50. PubMed ID: 16513458
[TBL] [Abstract][Full Text] [Related]
51. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
[TBL] [Abstract][Full Text] [Related]
52. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study.
Liang H; Brignole-Baudouin F; Pauly A; Riancho L; Baudouin C
Adv Ther; 2011 Apr; 28(4):311-25. PubMed ID: 21424577
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
[TBL] [Abstract][Full Text] [Related]
54. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study.
Macky TA
J Ocul Pharmacol Ther; 2010 Dec; 26(6):605-10. PubMed ID: 21034177
[TBL] [Abstract][Full Text] [Related]
55. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
Ozturk F; Ermis SS; Inan UU
Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
[TBL] [Abstract][Full Text] [Related]
56. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
57. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension.
Hepsen IF; Ozkaya E
Eye (Lond); 2007 Apr; 21(4):453-8. PubMed ID: 16543930
[TBL] [Abstract][Full Text] [Related]
58. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
59. Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma.
Holló G; Kóthy P
Curr Med Res Opin; 2008 Jun; 24(6):1755-61. PubMed ID: 18479590
[TBL] [Abstract][Full Text] [Related]
60. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension.
Cohen JS; Gross RL; Cheetham JK; VanDenburgh AM; Bernstein P; Whitcup SM
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S45-52. PubMed ID: 15016561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
